Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

QING CATHERINE ZHAO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1548400161
CMS profile
663598
Location
GILBERT, AZ

General Payments · PY2018–2024

$12,093.43

  • Reported across 49 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$915.84

16 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $565.84 15
Grant $350.00 1

By paying entity

PY2024 · sorted by reported total

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $81.32 6
PY2019 $81.25 6
PY2021 $2,509.42 2
PY2022 $8,072.62 11
PY2023 $432.98 8
PY2024 $915.84 16

Payment records · PY2024 (16)

Sorted by paying entity, then date · as published by CMS

Program year 2024 20182019202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $33.82 05/10/2024 Food and Beverage Undisputed 01/23/2026 1104448939 CMS
AstraZeneca Pharmaceuticals LP $350.00 06/03/2024 Grant Undisputed 01/23/2026 1104661429 CMS
Gilead Sciences, Inc. $3.77 06/14/2024 Food and Beverage Undisputed 01/23/2026 1133803942 CMS
Gilead Sciences, Inc. $15.04 09/21/2024 Food and Beverage Undisputed 01/23/2026 1133803944 CMS
Gilead Sciences, Inc. $113.75 12/11/2024 Food and Beverage Undisputed 01/23/2026 1133803946 CMS
Lilly USA, LLC $40.74 12/11/2024 Food and Beverage Undisputed 01/23/2026 1135328595 CMS
Novartis Pharmaceuticals Corporation $41.96 03/19/2024 Food and Beverage Undisputed 01/23/2026 1087440904 CMS
Novartis Pharmaceuticals Corporation $31.82 06/02/2024 Food and Beverage Undisputed 01/23/2026 1087440906 CMS
PFIZER INC. $22.13 02/14/2024 Food and Beverage Undisputed 01/23/2026 1131280438 CMS
PFIZER INC. $87.46 05/31/2024 Food and Beverage Undisputed 01/23/2026 1131320592 CMS
PFIZER INC. $28.81 07/30/2024 Food and Beverage Undisputed 01/23/2026 1131356951 CMS
PFIZER INC. $28.47 11/10/2024 Food and Beverage Undisputed 01/23/2026 1131389331 CMS
PFIZER INC. $0.89 11/11/2024 Food and Beverage Undisputed 01/23/2026 1131381684 CMS
PFIZER INC. $8.25 12/03/2024 Food and Beverage Undisputed 01/23/2026 1131392685 CMS
Pharmacosmos Therapeutics Inc. $71.50 01/25/2024 Food and Beverage Undisputed 01/23/2026 1154827269 CMS
TerSera Therapeutics LLC $37.43 01/18/2024 Food and Beverage Undisputed 01/23/2026 1144717651 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.